We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Astellas Pharma has signed an exclusive licensing agreement to develop and commercialise Frequency Therapeutics’ drug candidate FX-322 for sensorineural hearing loss.
Updated public list of companies in the UK who have had their licence/registration to manufacture or wholesale medicines/ingredients revoked or suspended…